1.30Open1.30Pre Close0 Volume33 Open Interest10.00Strike Price0.00Turnover316.22%IV7.62%PremiumJul 19, 2024Expiry Date0.50Intrinsic Value100Multiplier2DDays to Expiry0.80Extrinsic Value100Contract SizeAmericanOptions Type0.6258Delta0.1430Gamma8.08Leverage Ratio-0.2459Theta0.0003Rho5.05Eff Leverage0.0032Vega
Kyverna Therapeutics Stock Discussion
Kyverna's KYV-101 Receives U.S. FDA RMAT Designation for KYV-101 in the Treatment of Patients With Refractory Stiff-Person Syndrome
Kyverna Therapeutics (KYTX) has received Regenerative Medicine Advanced Therapy (RMAT) designation from the FDA for KYV-101, its autologous CD19 CAR T-cell therapy, in treating refractory stiff-person syndrome. This designation, based on positive clinical outcomes in Germany, allows Kyverna to receive expert guidance on efficient ...
No comment yet